Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
September 12, 2023 4:06 PM 2 min read

FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch

by Vandana Singh Benzinga Editor
Follow

ArticleFeaturedTickersList12345!!!

According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for relief from a stuffy nose, is likely no better than a dummy pill.

"We believe that these new clinical pharmacology and clinical data are consistent, substantial, and believable, and they confirm that orally administered [phenylephrine] is not effective at any dose that can be developed and still provide a reasonable margin of safety," the agency's reviewers wrote in their report.

Advisers to the FDA voted unanimously against the effectiveness of the phenylephrine found in popular versions of Benadryl, Mucinex, Tylenol, and other medications stocked on store shelves.

For the panel's recommendations, three oral decongestant ingredients, phenylpropanolamine (PPA), pseudoephedrine (PSE), and phenylephrine hydrochloride, were included.

PPA was removed from OTC use due to safety issues.

After the Combat Methamphetamine Epidemic Act of 2005, PSE became regulated as 'behind-the-counter,' limiting its use in the OTC setting and leaving PE as the only remaining OTC oral decongestant.

If the FDA follows through on the panel's recommendations, Johnson & Johnson's (NYSE:JNJ) recent spinoff Kenvue Inc (NYSE:KVUE), Bayer AG (OTC:BAYRY), GSK Plc's (NYSE:GSK) spinoff Haleon Plc (NYSE: HLN), and Procter & Gamble Company (NYSE: PG), Reckitt Benckiser Group (OTC: RBGLY) (OTC: RBGPF) and other drugmakers could be required to pull their oral medications containing phenylephrine from store shelves. 

The manufacturers and pharmacy retailers could also see some impact if the FDA deems phenylephrine ineffective.

Wall Street Journal, citing Research firm IRI, notes that in 2021, OTC products designed to address cough, sinus, and flu symptoms, including phenylephrine-containing pills, generated approximately $5 billion in sales.

Pharmacy retailers to watch out for include CVS Health Inc (NYSE: CVS), Walgreens Boots Alliance Inc (NASDAQ: WBA), and Rite Aid Corp (NYSE: RAD), among others.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Large CapNewsPenny StocksHealth CareFDAGeneralBriefs
HLN Logo
HLNHaleon PLC
$10.99-%
Overview
KVUE Logo
KVUEKenvue Inc
$18.40-%
BAYRY Logo
BAYRYBayer AG
$13.65-%
CVS Logo
CVSCVS Health Corp
$75.70-%
GSK Logo
GSKGSK PLC
$58.68-%
JNJ Logo
JNJJohnson & Johnson
$238.97-%
PG Logo
PGProcter & Gamble Co
$159.15-%
RBGLY Logo
RBGLYReckitt Benckiser Group PLC ADR
$16.67-4.00%
RBGPF Logo
RBGPFReckitt Benckiser Group PLC
$83.96-3.85%
HLN Logo
HLNHaleon PLC
$10.99-%
Overview
KVUE Logo
KVUEKenvue Inc
$18.40-%
BAYRY Logo
BAYRYBayer AG
$13.65-%
CVS Logo
CVSCVS Health Corp
$75.70-%
GSK Logo
GSKGSK PLC
$58.68-%
JNJ Logo
JNJJohnson & Johnson
$238.97-%
PG Logo
PGProcter & Gamble Co
$159.15-%
RBGLY Logo
RBGLYReckitt Benckiser Group PLC ADR
$16.67-4.00%
RBGPF Logo
RBGPFReckitt Benckiser Group PLC
$83.96-3.85%
Comments
Loading...